YouTube · H1 2026 · 2026-08-23
PAHC · NasdaqGM
Phibro Animal Health Corporation
Drug Manufacturers - Specialty & Generic · United States
USD 34.560.3% daily changeQuote 2026-09-18 · USD
- Market cap (USD)
- US$1.40B
- Trailing P/E
- 14.22x
- Forward P/E
- 8.98x
- Quarterly revenue growth
- 4.8%
- Trailing net margin
- 6.6%
- Indicated dividend yield
- 1.4%
Snapshot 2026-09-20 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-11-04 (provider estimate, not issuer-confirmed).
Company background
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
Company websiteQ4 FY2026
Go beyond the headline.
PAHC Stock Q4 FY2026: A Record Year, And 3.9% Of It Became Cash
Published 2026-08-28
Comparable businesses
PAHC peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | PAHCPhibro Animal Health CorporationSnapshot 2026-09-20Financial period: 2026-06-30 | ALVOAlvotechSnapshot 2026-09-20Financial period: 2026-06-30 | HCMHUTCHMED (China) LimitedSnapshot 2026-09-20Financial period: 2026-06-30 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$1.40B | US$2.09B | US$2.38B | US$2.24Bn=2 |
| Forward P/EProvider forward earnings estimate | 8.98x | 25.71x | 52.40x | 39.05xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | 8.66x | 44.94x | — | — |
| Revenue growthLatest quarter vs prior-year quarter | 4.8% | -38.9% | 0.2% | -19.3%n=2 |
| Operating marginLatest reported quarter | 10.6% | -11.1% | 0.3% | -5.4%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | -1.4% | -5.9% | -0.8% | -3.3%n=2 |
| Net debt / EBITDANet debt / trailing EBITDA | 2.91x | 17.28x | — | — |
| Debt / equityTotal debt / positive book equity | 2.06x | — | 0.07x | — |
| Trailing P/ETrailing twelve-month earnings | 14.22x | — | 136.70x | — |
| Price / bookPrice / positive book equity per share | 3.64x | — | 1.88x | — |
| EV / salesEnterprise value / trailing revenue | 1.39x | 6.88x | 2.02x | 4.45xn=2 |
| Earnings growthLatest quarter vs prior-year quarter | 24.6% | — | -96.5% | — |
| Gross marginTrailing twelve months | 33.3% | 60.7% | 13.3% | 37.0%n=2 |
| Net marginTrailing twelve months | 6.6% | -36.3% | 3.3% | -16.5%n=2 |
| Return on equityProvider trailing return; positive equity only | 29.7% | — | 1.5% | — |
| Free cash flow marginTrailing free cash flow / revenue | -1.3% | -24.9% | -3.4% | -14.2%n=2 |
| Dividend yieldIndicated annual dividend / price | 1.4% | — | — | — |
| Earnings payoutProvider trailing dividend payout | 19.8% | 0.0% | 0.0% | 0.0%n=2 |
| Current ratioCurrent assets / current liabilities | 2.96x | 1.65x | 5.64x | 3.65xn=2 |
| BetaProvider historical market sensitivity | 0.47 | 0.22 | 0.45 | 0.33n=2 |
YouTube · H1 2026 · 2026-08-23
HUTCHMED (China) Limited (HCM)
Similar size · 1.69x market cap
Drug Manufacturers - Specialty & Generic
YouTube · Q1 2026 · 2026-06-05
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-09-20. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for PAHC
Q4 FY20262026-08-28
PAHC Stock Q4 FY2026: A Record Year, And 3.9% Of It Became Cash
Presentation · 2026-08-28 · YouTube